Market Overview

Morgan Stanley Remains Confident In CIGNA Following Management Visit

Related CI
Benzinga's Top Upgrades
Sterne Agee CRT Upgrades Anthem And Cigna To Buy, Sees 24% Upside
Anthem Improves Q2 Cost Ratio But Humana's Worsens (Investor's Business Daily)

In a report published Wednesday, Morgan Stanley analyst Andrew Schenker reiterated an Overweight rating and $99.00 price target on CIGNA (NYSE: CI).

In the report, Morgan Stanley noted, “Expect continued improvement in Medicare. Cigna may not see the full benefit of some of the triage activities it implemented to improve the Medicare business in 2H13 until 2H14. The measures included identifying underperforming facilities, renegotiating reimbursement rates, and modifying networks where necessary. Recall, the company has not incorporated any improvement in Medicare in its FY14 outlook. In addition, Cigna anticipates an improvement in Medicare margins in FY15 as it continues to enhance networks and products.”

CIGNA closed on Tuesday at $89.12.

Latest Ratings for CI

Jul 2015Sterne AgeeUpgradesNeutralBuy
Jul 2015SusquehannaMaintainsPositive
Jun 2015RBC CapitalInitiates Coverage onSector Perform

View More Analyst Ratings for CI
View the Latest Analyst Ratings

Posted-In: Andrew Schenker Morgan StanleyAnalyst Color Reiteration Analyst Ratings


Related Articles (CI)

Get Benzinga's Newsletters